Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

@article{Abifadel2003MutationsIP,
  title={Mutations in PCSK9 cause autosomal dominant hypercholesterolemia},
  author={M. Abifadel and M. Varret and J. Rab{\`e}s and D. Allard and K. Ouguerram and M. Devillers and C. Cruaud and S. Benjannet and L. Wickham and D. Erlich and A. Derr{\'e} and L. Vill{\'e}ger and M. Farnier and I. Beucler and E. Bruckert and J. Chambaz and B. Chanu and Jean-Michel Lecerf and G. Luc and P. Moulin and J. Weissenbach and Annick Prat and M. Krempf and C. Junien and N. Seidah and C. Boileau},
  journal={Nature Genetics},
  year={2003},
  volume={34},
  pages={154-156}
}
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9… Expand
2,183 Citations

Paper Mentions

Interventional Clinical Trial
Clinical Trial Phase III, experimental, simple blind, randomized with two treatment groups, multicentric, longitudinal, to evaluate the therapuetic efficacy to dislipydemias in mexican… Expand
ConditionsCardiovascular Risk Factor, Dyslipidemias
InterventionDrug
Interventional Clinical Trial
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for… Expand
ConditionsAtherosclerotic Cardiovascular Disease, Diabetes, Familial Hypercholesterolemia
InterventionDrug
Interventional Clinical Trial
This research add resistance training to patients who undergo cardiac rehabilitation program after coronary bypass surgery, comparing the level of PCSK9 level on that group to another… Expand
ConditionsCoronary Artery Disease
InterventionBehavioral
Blog Post
Genetic heterogeneity of autosomal dominant hypercholesterolemia
  • 166
LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population.
  • 29
Mutations in STAP1 Are Associated With Autosomal Dominant Hypercholesterolemia
  • 97
  • PDF
APOE p.Leu167del mutation in familial hypercholesterolemia.
  • 61
PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
  • Highly Influenced
Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9
  • 173
  • PDF
A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.
  • 23
  • PDF
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
  • T. Leren
  • Biology, Medicine
  • Clinical genetics
  • 2004
  • 233
...
1
2
3
4
5
...

References

SHOWING 1-8 OF 8 REFERENCES
A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32.
  • 156
Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred.
  • 102
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation
  • 885
  • PDF
Biosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
  • 98
  • PDF
A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood.
  • M. Brown, J. Goldstein
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
  • 1,252
  • PDF
RGD and other recognition sequences for integrins.
  • E. Ruoslahti
  • Biology, Medicine
  • Annual review of cell and developmental biology
  • 1996
  • 2,675
Arterioscler. Thromb
  • Vasc. Biol. 20,
  • 2000
N at u re P u b lis h in g G ro u p h tt p :/ /w w w .n at u re .c o m
  • Rev. Cell. Dev. Biol
  • 1996